newsfilter
← Latest News
GlobeNewswire·

Bioxytran Completes Production of Two Dietary Supplements: V-LO® for Immune Health and A-SUQAR® for Healthy Blood Sugar

BIXT
  • Bioxytran, Inc. completed manufacturing finished inventory for two dietary supplements: V-LO® for immune support & A-SUQAR® for post-meal blood sugar support within the normal range.
  • Both product names are registered trademarks with the USPTO & the company is currently finalizing go-to-market plans including e-commerce, retail, & distribution channels.
  • V-LO® is a 2-gr polysaccharide chewable tablet taken 5 times daily, targeting the global immune health supplements market projected to reach USD 67.79 billion by 2032.
  • A-SUQAR® is an oral chewable tablet taken before meals containing proprietary partially hydrolyzed polysaccharides that block enzymes digesting sugars to moderate blood sugar rise.
  • Bioxytran signed a commercial distribution agreement with Khoury Medical LTD in February 2026 to commercialize A-SUQAR® in the Middle East.
  • CEO David Platt stated that the company is now focused on building sales channels & expects to announce launch timing once plans are finalized.
  • The nutraceutical business operates separately from Bioxytran's pharmaceutical development programs in glycovirology, hypoxia, & degenerative disease.
  • No revenue has been generated from sales of V-LO® or A-SUQAR® as of the October 19, 2026 announcement date.
  • The company warned that forward-looking statements regarding marketing & sales are subject to risks including regulatory compliance, market acceptance, & financing.